Anticancer agent 357
Anticancer agent 357 is an orally active HER2 inhibitor. Anticancer agent 357 reduces the phosphorylation levels of HER2, AKT and GSK-3β, and downregulates the expression of β-catenin. Anticancer agent 357 inhibits the proliferation and migration of colon cancer cells with high HER2 expression, and suppresses tumor growth in xenograft models. Anticancer agent 357 can be used in colorectal cancer-related research.
For research use only. We do not sell to patients.
- Formula: C20H15F3N4
- Molecular Weight:368.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
HER2 |
GSK-3β |
Akt |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCM460 | IC50 |
38.62 μM
|
Inhibition of cell viability against human normal colon epithelial NCM460 cells incubated for 24 hrs by CCK-8 assay.
Inhibition of cell viability against human normal colon epithelial NCM460 cells incubated for 24 hrs by CCK-8 assay.
|
42492133 |
| LS174T | IC50 |
24.17 μM
|
Inhibition of cell viability against human colon cancer LS174T cells incubated for 24 hrs by CCK-8 assay.
Inhibition of cell viability against human colon cancer LS174T cells incubated for 24 hrs by CCK-8 assay.
|
42492133 |
| HCT-116 | IC50 |
29.74 μM
|
Inhibition of cell viability against human colon cancer HCT116 cells incubated for 24 hrs by CCK-8 assay.
Inhibition of cell viability against human colon cancer HCT116 cells incubated for 24 hrs by CCK-8 assay.
|
42492133 |
| NCM460 | IC50 |
21.18 μM
|
Inhibition of cell viability against human normal colon epithelial NCM460 cells incubated for 72 hrs by CCK-8 assay.
Inhibition of cell viability against human normal colon epithelial NCM460 cells incubated for 72 hrs by CCK-8 assay.
|
42492133 |
| LS174T | IC50 |
9.57 μM
|
Inhibition of cell viability against human colon cancer LS174T cells incubated for 72 hrs by CCK-8 assay.
Inhibition of cell viability against human colon cancer LS174T cells incubated for 72 hrs by CCK-8 assay.
|
42492133 |
| HCT-116 | IC50 |
9.71 μM
|
Inhibition of cell viability against human colon cancer HCT116 cells incubated for 72 hrs by CCK-8 assay.
Inhibition of cell viability against human colon cancer HCT116 cells incubated for 72 hrs by CCK-8 assay.
|
42492133 |
In Vitro
Anticancer agent 357 (compound 7) (0-40 μM; 24-72 h) inhibits the viability of LS174T and HCT116 colon cancer cells as well as NCM460 normal colonic epithelial cells in a dose- and time-dependent manner; after 72 h of incubation, its potency and selectivity against colon cancer cells are enhanced (IC50 values: 9.57 μM for LS174T cells, 9.71 μM for HCT116 cells)[1].
Anticancer agent 357 (20 μM; 24-48 h) significantly inhibits the proliferation and migration of LS174T and HCT116 colon cancer cells, as detected by scratch wound healing assay[1].
Anticancer agent 357 (30 μM; 0-24 h) inhibits the HER2/AKT/GSK-3β/β-catenin signaling pathway in LS174T and HCT116 colon cancer cells by reducing the phosphorylation levels of HER2, AKT and GSK-3β, and downregulating β-catenin protein expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human colon cancer LS174T cells, human colon cancer HCT116 cells, human normal colon epithelial NCM460 cells
-
Concentration:0, 1.5, 2.5, 5, 10, 20, 40 μM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Inhibited cell viability in all three cell lines in a concentration- and time-dependent manner.
Exhibited 24 h IC50 values of 38.62 μM (NCM460), 24.17 μM (LS174T), and 29.74 μM (HCT116).
Exhibited 72 h IC50 values of 21.18 μM (NCM460), 9.57 μM (LS174T), and 9.71 μM (HCT116).
Achieved selectivity index (SI) of 1.60 for LS174T and 1.30 for HCT116 at 24 h, and increased to 2.21 for LS174T and 2.18 for HCT116 at 72 h.
-
Cell Line:human colon cancer LS174T cells, human colon cancer HCT116 cells
-
Concentration:20 μM
-
Incubation Time:24 h
-
Result:Markedly inhibited migratory capacity of LS174T and HCT116 cells.
Resulted in significantly lower percent wound closure in both cell lines relative to the vehicle control.
-
Cell Line:human colon cancer LS174T cells, human colon cancer HCT116 cells
-
Concentration:20 μM
-
Incubation Time:48 h
-
Result:Suppressed colony formation by LS174T and HCT116 cells.
-
Cell Line:human colon cancer LS174T cells, human colon cancer HCT116 cells
-
Concentration:30 μM
-
Incubation Time:0, 2, 3, 4 h (HER2/AKT analysis)
0, 6, 9, 12 h (GSK-3β analysis)
24 h (β-catenin analysis) -
Result:Induced a time-dependent reduction in phosphorylation of HER2 (Tyr1221/1222) and AKT (Ser473) in both cell lines.
Caused a time-dependent decrease in phosphorylation of GSK-3β (Ser9) in both cell lines.
Downregulated β-catenin protein expression significantly in both cell lines after 24 h treatment relative to the control.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (4-6 weeks old)[1]
-
Dosage:25 mg/kg; 50 mg/kg
-
Administration:p.o.; daily; 14 days
-
Result:Significantly inhibited LS174T xenograft tumor growth relative to vehicle control.
Did not cause significant body weight loss.
Exhibited a more pronounced inhibitory effect at 50 mg/kg than at 25 mg/kg.
Significantly reduced tumor weights in both treatment groups compared to vehicle control.\nSignificantly inhibited HCT116 xenograft tumor growth relative to vehicle control.
Did not cause significant body weight loss.
Significantly reduced tumor weights in both treatment groups compared to vehicle control.
Chemical Information
-
Molecular Weight 368.36
-
Formula C20H15F3N4
-
SMILES
FC(F)(F)C1=CC=C(C2=NN3C(NCC[C@@H]3C4=CC=CC=C4)=C2C#N)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)